Standard BioTools (LAB) Expected to Announce Earnings on Wednesday

Standard BioTools (NASDAQ:LAB) will likely be posting its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect Standard BioTools to post earnings of ($0.07) per share and revenue of $43.03 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Standard BioTools Stock Up 2.3 %

Standard BioTools stock opened at $1.33 on Tuesday. Standard BioTools has a 52-week low of $1.17 and a 52-week high of $3.04. The firm has a market capitalization of $495.11 million, a price-to-earnings ratio of -1.87 and a beta of 1.57. The company has a fifty day simple moving average of $1.67 and a 200-day simple moving average of $1.81.

Analysts Set New Price Targets

Separately, TD Cowen dropped their price objective on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a report on Thursday, October 31st.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.